{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:06:12Z","timestamp":1767143172453,"version":"build-2238731810"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02801-4","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:02:08Z","timestamp":1708387328000},"page":"1338-1350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy"],"prefix":"10.1007","volume":"41","author":[{"given":"LeighAnn Y.","family":"Vincik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra D.","family":"Dautel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail A.","family":"Staples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian V.","family":"Lauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery T.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4545-4523","authenticated-orcid":false,"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2801_CR1","unstructured":"Bladen CL, et al. Hum Mutat. 2015;36:394\u2013402."},{"key":"2801_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","volume":"2587","author":"RR Roshmi","year":"2023","unstructured":"Roshmi RR, Yokota T. Viltolarsen: from preclinical studies to FDA approval. Methods Mol Biol. 2023;2587:31\u201341. https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_2.","journal-title":"Methods Mol Biol"},{"issue":"10","key":"2801_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi RR, Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc). 2019;55(10):627\u201339. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045038.","journal-title":"Drugs Today (Barc)"},{"issue":"10","key":"2801_CR4","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168\u201384. https:\/\/doi.org\/10.3390\/molecules201018168.","journal-title":"Molecules"},{"issue":"9","key":"2801_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","volume":"20","author":"Y Nan","year":"2018","unstructured":"Nan Y, Zhang YJ. Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds. Front Microbiol. 2018;20(9):750. https:\/\/doi.org\/10.3389\/fmicb.2018.00750.","journal-title":"Front Microbiol"},{"key":"2801_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01639-x","author":"DT Michaeli","year":"2023","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2023. https:\/\/doi.org\/10.1007\/s10198-023-01639-x.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"2801_CR7","doi-asserted-by":"publisher","first-page":"e0265879","DOI":"10.1371\/journal.pone.0265879","volume":"17","author":"N Ferizovic","year":"2022","unstructured":"Ferizovic N, Summers J, de Z\u00e1rate IBO, et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE. 2022;17(3):e0265879. https:\/\/doi.org\/10.1371\/journal.pone.0265879.","journal-title":"PLoS ONE"},{"key":"2801_CR8","unstructured":"Venugopal V, Pavlakis S. Duchenne muscular dystrophy. Treasure Island (FL): StatPearls; 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482346\/. Accessed 18 Feb 2023."},{"issue":"1","key":"2801_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primers"},{"key":"2801_CR10","unstructured":"Houck, J. Published February 23, 2024. https:\/\/mdaquest.org\/all-50-states-and-dc-implement-spinal-muscular-atrophy-newborn-screening\/. Accessed 11 April 2024."},{"issue":"4","key":"2801_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27682","volume":"66","author":"FJ Weber","year":"2022","unstructured":"Weber FJ, Latshang TD, Blum MR, Kohler M, Wertli MM. Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: a systematic review and meta-analysis. Muscle Nerve. 2022;66(4):462\u201370. https:\/\/doi.org\/10.1002\/mus.27682.","journal-title":"Muscle Nerve"},{"issue":"14","key":"2801_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83(14):1323\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01929-x.","journal-title":"Drugs"},{"key":"2801_CR13","unstructured":"Viltepso (viltolarsen) dosing, indications, interactions, adverse effects, and more. https:\/\/reference.medscape.com\/drug\/viltepso-viltolarsen-4000040. Accessed 12 June 2023."},{"key":"2801_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TACG.S71506","volume":"7","author":"V Arechavala-Gomeza","year":"2014","unstructured":"Arechavala-Gomeza V, Khoo B, Aartsma-Rus A. Splicing modulation therapy in the treatment of genetic diseases. Appl Clin Genet. 2014;7:245\u201352. https:\/\/doi.org\/10.2147\/TACG.S71506.","journal-title":"Appl Clin Genet"},{"key":"2801_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne muscular dystrophy. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.950651.","journal-title":"Front Pharmacol"},{"issue":"s2","key":"2801_CR16","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.3233\/JND-210701","volume":"8","author":"ME Benny Klimek","year":"2021","unstructured":"Benny Klimek ME, Vila MC, Edwards K, et al. Effects of chronic, maximal phosphorodiamidate morpholino oligomer (PMO) dosing on muscle function and dystrophin restoration in a mouse model of Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8(s2):S369\u201381. https:\/\/doi.org\/10.3233\/JND-210701.","journal-title":"J Neuromuscul Dis"},{"key":"2801_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-0716-2010-6_14","volume-title":"Antisense RNA design, delivery, and analysis: methods in molecular biology","author":"A L\u00f3pez-Mart\u00ednez","year":"2022","unstructured":"L\u00f3pez-Mart\u00ednez A, Soblechero-Mart\u00edn P, Arechavala-Gomeza V. Evaluation of exon skipping and dystrophin restoration in in vitro models of duchenne muscular dystrophy. In: Arechavala-Gomeza V, Garanto A, editors. Antisense RNA design, delivery, and analysis: methods in molecular biology. New York: Springer; 2022. p. 217\u201333. https:\/\/doi.org\/10.1007\/978-1-0716-2010-6_14."},{"key":"2801_CR18","unstructured":"Amondys 45 (casimersen) dosing, indications, interactions, adverse effects, and more. https:\/\/reference.medscape.com\/drug\/amondys-45-casimersen-4000136#0. Accessed 12 June 2023."},{"key":"2801_CR19","unstructured":"Exondys 51 (eteplirsen) dosing, indications, interactions, adverse effects, and more. https:\/\/reference.medscape.com\/drug\/exondys-51-eteplirsen-1000020. Accessed 12 June 2023."},{"key":"2801_CR20","unstructured":"VILTEPSO. Prescribing information. NS Pharma, Inc.; 2021 https:\/\/www.viltepso.com\/prescribing-information. Accessed 11 Dec 2023."},{"key":"2801_CR21","unstructured":"NS Pharma, Inc. A phase\u00a02 open-label study to assess the safety, tolerability, and efficacy of viltolarsen in ambulant and non-ambulant boys with Duchenne muscular dystrophy (DMD) compared to natural history controls. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04956289. Accessed 12 June 2023."},{"key":"2801_CR22","unstructured":"NS Pharma, Inc. A phase\u00a03 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of viltolarsen in ambulant boys with Duchenne muscular dystrophy (DMD). clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04060199. Accessed 12 June 2023."},{"key":"2801_CR23","unstructured":"NS Pharma, Inc. A phase\u00a03, multi-center, open-label extension study to assess the safety and efficacy of viltolarsen in ambulant boys with Duchenne muscular dystrophy (DMD). clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768062. Accessed 12 June 2023."},{"key":"2801_CR24","unstructured":"NS Pharma, Inc. Long-term use of viltolarsen in boys with Duchenne muscular dystrophy in clinical practice (VILT-502). clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04687020. Accessed June 12 2023."},{"key":"2801_CR25","unstructured":"NS Pharma, Inc. The expanded access use of viltolarsen for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon\u00a053 skipping. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04337112. Accessed 12 June 2023."},{"key":"2801_CR26","unstructured":"Viltolarsen (Viltepso) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2020;62(1609):167."},{"key":"2801_CR27","unstructured":"Vyondys 53 (golodirsen) dosing, indications, interactions, adverse effects, and more. https:\/\/reference.medscape.com\/drug\/vyondys-53-golodirsen-1000334#10. Accessed 2 Jan 2024."},{"key":"2801_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009;65:667\u201376.","journal-title":"Ann Neurol"},{"key":"2801_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Nagata T, Satou Y, et al. NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon\u00a053 skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442\u20139. https:\/\/doi.org\/10.1016\/j.omtn.2018.09.017.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2801_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713","author":"H Komaki","year":"2018","unstructured":"Komaki H, et al. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon\u00a053 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aan0713.","journal-title":"Sci Transl Med"},{"issue":"12","key":"2801_CR31","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Takeshima Y, Matsumura T, et al. Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase\u00a01\/2 study. Ann Clin Transl Neurol. 2020;7(12):2393\u2013408. https:\/\/doi.org\/10.1002\/acn3.51235.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"2801_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon\u00a053 skipping: a phase\u00a02 randomized clinical trial. JAMA Neurol. 2020;77(8):982\u201391. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2801_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JND-220811","volume":"9","author":"PR Clemens","year":"2022","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Long-term functional efficacy and safety of viltolarsen in patients with duchenne muscular dystrophy. J Neuromuscul Dis. 2022;9(4):493\u2013501. https:\/\/doi.org\/10.3233\/JND-220811.","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"2801_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JND-221656","volume":"10","author":"PR Clemens","year":"2023","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase\u00a02, open-label, 4-year extension study. J Neuromuscul Dis. 2023;10(3):439\u201347. https:\/\/doi.org\/10.3233\/JND-221656.","journal-title":"J Neuromuscul Dis"},{"key":"2801_CR35","unstructured":"FDA approves targeted treatment for Rare Duchenne muscular dystrophy mutation. US Food and Drug Administration. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation."},{"issue":"13","key":"2801_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651","volume":"22","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne muscular dystrophy. Front Pharmacol. 2022;22(13): 950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651.","journal-title":"Front Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s12325-024-02909-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02801-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T02:23:43Z","timestamp":1722651823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02801-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02801-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-024-02909-7","URL":"https:\/\/doi.org\/10.1007\/s12325-024-02909-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and contains no new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}